Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.

Viral Interleukin-6 (vIL-6) is encoded by Human herpes virus 8 (HHV8), also known as Kaposi's sarcoma (KS)-associated herpes virus (KSHV). HHV8 infection is found in patients with KS, primary effusion lymphoma (PEL) and plasma cell-type of multicentric Castleman's disease (MCD), with a high incidence observed in HIV infected individuals. vIL-6 shares about 25% identity with its human counterpart. Human IL-6 (hIL-6) binds to the human IL-6 receptor (hIL-6R) and the hIL-6/hIL-6R complex associates with the signaling receptor subunit gp130. Upon dimerization of gp130 intracellular signaling is initiated. All cells in the body express gp130 but only some cell types express the hIL-6R. Human IL-6 does not stimulate cells, which do not express hIL-6R. However, a naturally occurring soluble form of the hIL-6R (shIL-6R) can bind hIL-6 and the complex of hIL-6/shIL-6R can stimulate cells, which only express gp130 but no hIL-6R. This process, which has been named trans-signaling, leads to a dramatic increase in the spectrum of hIL-6 target cells during inflammation and cancer. vIL-6, in contrast to hIL-6, can directly bind to and activate gp130 without the need of the hIL-6R. Therefore, at least in theory, vIL-6 can stimulate every cell in the human body. This review highlights the properties of vIL-6 regarding structural features, implications for pathophysiology, and strategies of neutralization. Furthermore, mechanisms of activation of gp130 by hIL-6, vIL-6, and by forced dimerization will be discussed.

[1]  P. Heinrich,et al.  Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor* , 2004, Journal of Biological Chemistry.

[2]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[3]  J. Grötzinger,et al.  The Structure of the Interleukin-15α Receptor and Its Implications for Ligand Binding* , 2006, Journal of Biological Chemistry.

[4]  C. D. Dela Cruz,et al.  Complex N-Linked Glycans on Asn-89 of Kaposi Sarcoma Herpes Virus-encoded Interleukin-6 Mediate Optimal Function by Affecting Cytokine Protein Conformation* , 2009, The Journal of Biological Chemistry.

[5]  G. Wood,et al.  Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. , 1985, The American journal of pathology.

[6]  M. Pocock,et al.  Crystal Structure of the Entire Ectodomain of gp130 , 2010, The Journal of Biological Chemistry.

[7]  P. Moore,et al.  Viral IL-6-Induced Cell Proliferation and Immune Evasion of Interferon Activity , 2002, Science.

[8]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[9]  K. Garcia,et al.  Shared cytokine signaling receptors: structural insights from the gp130 system. , 2004, Advances in protein chemistry.

[10]  G. Ciliberto,et al.  Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. , 1998, Blood.

[11]  Stefan Rose-John,et al.  Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane , 2005, Protein science : a publication of the Protein Society.

[12]  G. Tosato,et al.  Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. , 1999, Blood.

[13]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[14]  F. Neipel,et al.  Human herpesvirus 8 encodes a homolog of interleukin-6 , 1997, Journal of virology.

[15]  P. Heinrich,et al.  Importance of the Membrane-Proximal Extracellular Domains for Activation of the Signal Transducer Glycoprotein 1301 , 2000, The Journal of Immunology.

[16]  P. Heinrich,et al.  Intracellular retention of interleukin-6 abrogates signaling. , 1993, The Journal of biological chemistry.

[17]  C. Fielding,et al.  Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation1 , 2005, The Journal of Immunology.

[18]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[19]  S. Kamel‐Reid,et al.  Immunoglobulin and T‐cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis , 2006, Histopathology.

[20]  K. Lennert,et al.  Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant , 1989, Histopathology.

[21]  S. Rose-John,et al.  Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells , 2002, AIDS.

[22]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[23]  K. Garcia,et al.  Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor , 2005, Nature Structural &Molecular Biology.

[24]  R. Inagi,et al.  Human herpesvirus 8‐encoded interleukin‐6 homologue (viral IL‐6) induces endogenous human IL‐6 secretion , 2000, Journal of medical virology.

[25]  F. Cicuttini,et al.  Targeting IL-6 in the treatment of inflammatory and autoimmune diseases , 2009, Expert opinion on investigational drugs.

[26]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[27]  K. Garcia,et al.  Structure of an Extracellular gp130 Cytokine Receptor Signaling Complex , 2001, Science.

[28]  D. Dittmer,et al.  Role of Notch Signal Transduction in Kaposi's Sarcoma-Associated Herpesvirus Gene Expression , 2005, Journal of Virology.

[29]  Yannick Jacques,et al.  Soluble IL-15Rα sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ: hyper-agonist IL-15-IL-15Rα fusion proteins , 2005 .

[30]  K. Garcia,et al.  A structural template for gp130-cytokine signaling assemblies. , 2002, Biochimica et biophysica acta.

[31]  M. Bower,et al.  Fifty years of multicentric Castleman's disease , 2004, Acta oncologica.

[32]  A. Iwamoto,et al.  Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. , 2000, Blood.

[33]  T. Kishimoto,et al.  Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. , 2001, Blood.

[34]  K. Garcia,et al.  Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. , 2004, Journal of molecular biology.

[35]  P. Galle,et al.  IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-61 , 2000, The Journal of Immunology.

[36]  L. D. Ward,et al.  High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. , 1994, The Journal of biological chemistry.

[37]  M. Reitz,et al.  Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. , 1998, Journal of the National Cancer Institute. Monographs.

[38]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. , 2007, Cancer research.

[39]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[40]  P. Galle,et al.  Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. , 2000, European journal of biochemistry.

[41]  Y. Chang,et al.  KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. , 1999, Human immunology.

[42]  J. Nicholas,et al.  Signal Transduction by Human Herpesvirus 8 Viral Interleukin-6 (vIL-6) IsModulated by the Nonsignaling gp80 Subunit of the IL-6 Receptor Complex and Is Distinct from Signaling Induced by Human IL-6 , 2006, Journal of Virology.

[43]  J. Nicholas,et al.  Human Herpesvirus 8 Interleukin-6 (vIL-6) Signals through gp130 but Has Structural and Receptor-Binding Properties Distinct from Those of Human IL-6 , 1999, Journal of Virology.

[44]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Yarchoan,et al.  Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. , 2001, Blood.

[46]  J. Scheller,et al.  Forced Homo- and Heterodimerization of All gp130-Type Receptor Complexes Leads to Constitutive Ligand-independent Signaling and Cytokine-independent Growth , 2010, Molecular biology of the cell.

[47]  T. Hirano,et al.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Lauffenburger,et al.  Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130‐Mediated Embryonic Stem Cell Self‐Renewal Responses to LIF and HIL‐6 , 2002, Stem cells.

[49]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[50]  G. Sandford,et al.  Intracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6 , 2008, Journal of Virology.

[51]  J. Tavernier,et al.  Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.

[52]  E. Cesarman,et al.  Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. , 1999, The Journal of infectious diseases.

[53]  Stefan Rose-John,et al.  Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display , 2006, Journal of Virology.

[54]  K. Garcia,et al.  Elucidation of the interleukin-15 binding site on its alpha receptor by NMR. , 2007, Biochemistry.

[55]  M. Meads,et al.  Kaposi's Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6 , 2004, Journal of Biological Chemistry.

[56]  A. Stansfeld,et al.  An immunohistological and genotypic study of the plasma cell form of Castleman's disease , 1989, Histopathology.

[57]  G. Ciliberto,et al.  Two distinct and independent sites on IL‐6 trigger gp 130 dimer formation and signalling. , 1995, The EMBO journal.

[58]  Xiu-fen Lei,et al.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis. , 2007, Cancer treatment and research.

[59]  C. D. Dela Cruz,et al.  N-linked Glycosylation Is Required for Optimal Function of Kaposi's Sarcoma Herpesvirus–encoded, but Not Cellular, Interleukin 6 , 2004, The Journal of experimental medicine.

[60]  J. Scheller,et al.  Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor , 2009, Journal of Virology.

[61]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[62]  R. Sun,et al.  Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease , 1999, Journal of Virology.

[63]  S. Pittaluga,et al.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. , 2001, Blood.

[64]  Hong Li,et al.  Detection of Direct Binding of Human Herpesvirus 8-Encoded Interleukin-6 (vIL-6) to both gp130 and IL-6 Receptor (IL-6R) and Identification of Amino Acid Residues of vIL-6 Important for IL-6R-Dependent and -Independent Signaling , 2001, Journal of Virology.

[65]  P S Kim,et al.  Preferential heterodimer formation by isolated leucine zippers from fos and jun. , 1989, Science.

[66]  J. Grötzinger.  Molecular mechanisms of cytokine receptor activation. , 2002, Biochimica et biophysica acta.

[67]  M. Corbellino,et al.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. , 2000, The American journal of pathology.

[68]  P. Heinrich,et al.  Orientational Constraints of the gp130 Intracellular Juxtamembrane Domain for Signaling* , 2002, The Journal of Biological Chemistry.

[69]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[70]  Stefan Rose-John,et al.  Virokines in the Pathogenesis of Cancer: Focus on Human Herpesvirus 8 , 2004, Annals of the New York Academy of Sciences.

[71]  Stefan Rose-John,et al.  Structure-guided Optimization of the Interleukin-6 Trans-signaling Antagonist sgp130* , 2008, Journal of Biological Chemistry.

[72]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[73]  P. Heinrich,et al.  Two Different Epitopes of the Signal Transducer gp130 Sequentially Cooperate on IL-6-Induced Receptor Activation1 , 2000, The Journal of Immunology.

[74]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Steinberg,et al.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  U. Klingmüller,et al.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. , 2006, Molecular biology of the cell.

[77]  J. Scheller,et al.  Synthetic Mimetics of the gp130 Binding Site for Viral Interleukin‐6 as Inhibitors of the vIL‐6–gp130 Interaction , 2008, Chemical biology & drug design.

[78]  P. Musiani,et al.  Coexpression of IL‐6 and soluble IL‐6R causes nodular regenerative hyperplasia and adenomas of the liver , 1998, The EMBO journal.

[79]  M. Goldsmith,et al.  A Kaposi’s Sarcoma-associated Herpesvirus-encoded Cytokine Homolog (vIL-6) Activates Signaling through the Shared gp130 Receptor Subunit* , 1997, The Journal of Biological Chemistry.

[80]  E. Jaffe,et al.  Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. , 1999, Blood.

[81]  P. Schirmacher,et al.  Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. , 1998, The American journal of pathology.

[82]  S. Henderson,et al.  Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma , 2004, Nature Genetics.

[83]  S. Rose-John,et al.  IL-6 Type Cytokine Receptor Complexes: Hexamer, Tetramer or Both? , 1999, Biological chemistry.

[84]  J. Scheller,et al.  Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. , 2008, Blood.

[85]  S. Schreiber,et al.  N-Linked Glycosylation Is Essential for the Stability but Not the Signaling Function of the Interleukin-6 Signal Transducer Glycoprotein 130* , 2009, The Journal of Biological Chemistry.

[86]  P. Schirmacher,et al.  Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6–sIL-6R Double Transgenic Mice , 1997, The Journal of experimental medicine.